viewOpen Orphan PLC

Full interview: Open Orphan confirms hVIVO deal is done

Cathal Friel, CEO of Open Orphan announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like.
News here on the Genomic Database and how Friel expects hVIVO to make a profit. Confirmation too on the slight musical chairs within management with Friel himself ceasing to be CEO and moving to a more 'hands on' Chairman's role. Friel explains a fundraiser is next and tells investors how he expects the revenue growth between both companies to grow.

Quick facts: Open Orphan PLC

Price: 6.45 GBX

Market: AIM
Market Cap: £28.74 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...



Full interview: Open Orphan hails huge new deal leading to stronger revenues

Open Orphan (LON:ORPH) has hailed a new three-year contract with a ‘tier-one’ German pharmaceuticals company. Stepping up to Executive Chairman from CEO, Cathal Friel tells Proactive London his new role will be focussing on investor relations and 'telling the story'. He's excited about the story...

2 weeks, 1 day ago


Update on Placing

2 days, 1 hour ago

Holding(s) in Company

2 days, 22 hours ago

Holding(s) in Company

2 days, 22 hours ago

Holding(s) in Company

3 days, 18 hours ago

Holding(s) in Company

4 days, 15 hours ago

2 min read